MedTrace Logo

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-01-07

No results posted yet for this study

Summary

Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of AI-09, a Ready-to-Use Liquid Injectable Botulinum Toxin.

Conditions

  • Glabellar Lines

Interventions

BIOLOGICAL

AI-09 Ready Use Injectable Botulinum Toxin

AI-09 Ready Use Injectable Botulinum Toxin

BIOLOGICAL

Vehicle

Vehicle

Sponsors & Collaborators

  • Eirion Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-03
Primary Completion
2026-02-28
Completion
2026-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07321834 on ClinicalTrials.gov